PMV Pharma(PMVP)

Focus: PMV Pharma is a public oncology-focused biotech company specializing in P53 regulators with a pipeline of early-stage programs targeting solid tumors and hematologic malignancies. The company operates at mid-cap scale with 201-500 employees and is headquartered in Princeton, NJ.

Oncology

Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

201-500

Open Jobs

About PMV Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow PMV Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PC14586

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT06362642A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants

Phase 1

Help build intelligence for PMV Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused technology platform (P53 regulators) in high-value oncology market with potential for multiple clinical shots on goal
Public company status provides liquidity and institutional credibility, distinct from pre-revenue stage risk
Early-stage pipeline allows opportunity to shape development strategy and clinical programs from formative phases

Watch Out For

Pre-revenue biotech with $68.96M net loss in FY2025 and only $41M cash on hand creates near-term sustainability pressure
No active job openings reported despite public status, suggesting hiring freeze or minimal near-term expansion plans
All pipeline programs in Phase 1/1-2 with no Phase 3 data or upcoming PDUFA dates—significant clinical and timelines uncertainty

Generated by Claude from PMV Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

[14C]-PC14586

Healthy Male Volunteers

PHASE_1

Clinical Trials (1)

NCT05523687AME Study of [14C]-PC14586 in Healthy Male Participants

Phase 1

PC14586

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT06054464A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

Phase 1

PC14586

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05249348Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

Phase 1

Azacitidine

Myelodysplastic Syndrome

PHASE_1

Clinical Trials (1)

NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Phase 1

metformin hydrochloride 500 mg tablet

TP53 Y220C Mutation

PHASE_1

Clinical Trials (1)

NCT07372625A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Phase 1

rezatapopt

Advanced Solid Tumor

PHASE_1_2